Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Autoimmune Limbic Encephalitis in Patients With Hematologic Malignancies After Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide

These authors contributed equally to this work.
Version 1 : Received: 9 May 2023 / Approved: 10 May 2023 / Online: 10 May 2023 (07:46:24 CEST)

How to cite: Heo, B.Y.; Lee, M.; Choi, S.; Jung, Y.; Pham, T.T.D.; Jang, Y.; Park, J.; Kang, S.; Koh, J.S.; Jo, D.; Kwon, J.; Song, I. Autoimmune Limbic Encephalitis in Patients With Hematologic Malignancies After Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide. Preprints 2023, 2023050700. https://doi.org/10.20944/preprints202305.0700.v1 Heo, B.Y.; Lee, M.; Choi, S.; Jung, Y.; Pham, T.T.D.; Jang, Y.; Park, J.; Kang, S.; Koh, J.S.; Jo, D.; Kwon, J.; Song, I. Autoimmune Limbic Encephalitis in Patients With Hematologic Malignancies After Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide. Preprints 2023, 2023050700. https://doi.org/10.20944/preprints202305.0700.v1

Abstract

Autoimmune limbic encephalitis (LE) is a rare, but devastating complication of allogeneic hem-atopoietic stem cell transplantation (HSCT). There is currently limited evidence describing the risk factors, laboratory features, and underlying mechanisms of this neurologic adverse event. We retrospectively reviewed available clinical, imaging, and laboratory data from adult patients with hematological malignancies who underwent haploidentical HSCT with cyclophosphamide (PTCy) at Chungnam National University Hospital from June 2016 to May 2020. Patients who developed LE were compared to those who did not based on clinical assessment, serum inflam-matory biomarkers, and reconstitution of various T cell populations. Of 35 patients, four devel-oped LE. There were no differences in patient demographics, donor demographics, or treatment conditions between patients that did and did not develop LE. Overall, patients with LE had worse clinical outcomes and overall survival than those without. In addition, they tended to have higher markers of systemic inflammation in the early post-transplant period, including fever, C-reactive protein (CRP), and cytokines. Remarkably, baseline interleukin-6 levels before HSCT were found to be higher in patients who developed LE than those who did not. In addition, analysis of T cell subsets showed impaired expansion of CD25+FOXP3+ regulatory T (Treg) cells in LE compared to non-LE patients despite appropriate reconstitution of the total CD4+ T cell population. Patients that developed LE within the first 30 days of HSCT were likely to have high serum IL-6 among other inflammatory cytokines coupled with suppression of regulatory T cell differentiation. Further work is needed on the mechanisms underlying impaired Treg expansion following HSCT and potential therapies.

Keywords

allogeneic hematopoietic stem cell transplantation; autoimmune limbic encephalitis; cyclo-phosphamide; regulatory T cells; CD25; Foxp3; IL-6; fever; acute graft-versus-host disease; cyto-kine-release syndrome

Subject

Medicine and Pharmacology, Hematology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.